Q.01

How do I prepare a CTD dossier?

A CTD dossier always has five modules, set out in ICH M4. Module 1 is regional administrative information. Modules 2 to 5 are common to all ICH regions, and if you follow the guideline they will be in a format the authorities accept [1]. M4 sets the format only. It says it "is not intended to indicate what studies are required", and applicants "should not modify the overall organisation" of the CTD. You may adjust individual formats only within the nonclinical and clinical summaries [2].

Approach: I used the ICH M4 family of guidelines (M4(R4), M4Q(R1), M4S(R2), M4E(R2)) and the EU Notice to Applicants Volume 2B and application forms. For eCTD requirements I opened the FDA eCTD page and EMA's eSubmission eCTD page; I did not check Japan's or other regions' Module 1 rules.

The practical sequence

1. Decide your region, procedure and electronic format first

  • EU: EMA states that eCTD "is mandatory to use for all submission types related to Marketing Authorisation" in the Centralised, Decentralised and Mutual Recognition Procedures. NeeS is now accepted only in some specific cases. The current EU Module 1 eCTD specification is v3.1.1 (EMA eSubmission eCTD).
  • US: the FDA requires eCTD for NDAs, ANDAs, BLAs, commercial INDs, all their later submissions, and master files including DMFs. It accepts both eCTD v3.2.2 and v4.0. From 16 October 2026, applications first submitted in v3.2.2 can move to v4.0 ("Forward Compatibility") (FDA eCTD).
  • Why this comes first: the recommended granularity for Modules 2.3 and 3 depends on the eCTD version you use, while Modules 4 and 5 use the same granularity under all versions [3]. eCTD v4.0 added an optional "blue" granularity level in Module 3 [4].

2. Build the technical modules (3, 4, 5) before the summaries. The summaries can only draw on what is in these modules.

  • Module 3 (Quality): follow the M4Q headings.
    • 3.2.S covers the drug substance and 3.2.P the drug product. For a product with more than one drug substance, give the "S" information in full for each one [5].
    • 3.2.R holds region-specific information, based on the relevant regional guidelines [6].
    • Choose document granularity with the product's whole lifecycle in mind. When information changes, you will need to provide replacement complete documents [5].
  • Module 4 (Nonclinical):
    • Present study reports in the order set by M4S [7].
    • The table of contents must include every numbered heading (e.g. 4.2.3.5.1) and go down to at least the individual study report [8].
  • Module 5 (Clinical):
    • Same rule: the table of contents goes down to each clinical study report, for example 5.3.5.1.1 Placebo Controlled Trials [9].
    • It includes 5.2, the Tabular Listing of All Clinical Studies [10].

3. Write Module 2 (summaries). The page lengths are ICH guidance, not hard limits.

SectionWhat it isGuidance on size
2.1 CTD table of contentsGoes to the 3rd or 4th level [11]; not applicable in eCTD [12]n/a
2.2 IntroductionPharmacologic class, mode of action, proposed clinical useShould not exceed one page [13]
2.3 Quality Overall SummaryFollows the scope and outline of Module 3. It should not include any information, data or justification that is not already in the CTD [14]n/a
2.4 Nonclinical OverviewAn integrated overall analysis [15]Should not exceed about 30 pages
2.6 Nonclinical Written and Tabulated Summariesn/aThe three written summaries together, in general, not over 100-150 pages [16]
2.5 Clinical OverviewA critical analysis that presents conclusions and implications and does not repeat the data [17]About 30 pages [18]
2.7 Clinical SummaryA detailed factual summary; sections 2.7.1 to 2.7.6 run from biopharmaceutics to study synopses [19]Usually 50-400 pages, excluding tables [20]

If you use control strategy summaries in Module 3, say in Module 2.3 (for example in the 2.3 Introduction) where they all are [21].

4. Assemble Module 1 to the regional rules (EU example)

  • 1.0 Cover letter and 1.2 Application form. The EU CTD Q&A shows this placement for Type IA/IB notifications, with the dossier-requirements checklist placed after the form [22].
  • 1.3.1 SmPC, labelling and package leaflet [22].
  • 1.7.1 and 1.7.2 orphan similarity sections, where the orphan questions on the application form apply [23].
  • 1.8.2 Risk Management Plan [24].
  • 1.10 Paediatrics: PIP or waiver decisions, PDCO opinion and compliance reports [25][26].

5. Apply the formatting rules throughout

  • Margins must allow printing on both A4 and 8.5 x 11" paper.
  • Times New Roman 12-point is recommended for narrative text.
  • Number every page according to the granularity document.
  • Define acronyms the first time they appear in each module.
  • Cite references in the ICMJE style [27].
  • Start each document's page numbering at one. Individual literature references can keep their journal page numbers [28].
  • List literature references in their own table of contents [29].
  • In eCTD, use the INN for the "substance" keyword. If there is no INN, a company code will do [30].

What goes into each section (which studies and how much data) is not set by the CTD format. It comes from the regional and ICH content guidance [31].

If you tell me the region, the procedure and the application type (e.g. new active substance, generic, variation), I can map the specific Module 1 and content requirements.

Q.02

How is an ASEAN dossier different?

An ASEAN dossier (the ASEAN Common Technical Dossier, ACTD) is in four Parts, not five Modules. It has no separate summary module: each Part carries its own overview or summary and then its data. Its biggest practical difference is that generics and minor variations do not need the nonclinical and clinical Parts. The ACTD was adopted in 2003, and the current text is Revision 1, endorsed by the ASEAN Pharmaceutical Product Working Group (ACCSQ-PPWG) in 2019 (ACTD Rev.1, Organisation of the Dossier, p.1).

Approach: The regulatory datasets hold the ICH M4 guidelines but no ASEAN pharmaceutical dossier guidance. So I read the ACTD Rev.1 "Organisation of the Dossier" and Part II (Quality) documents on the ASEAN Secretariat portal. I did not check individual ASEAN countries' national requirements or electronic-submission rules.

How ICH CTD modules map to ACTD Parts

ICH CTDACTD Rev.1
Module 1 (regional admin) + 2.1 ToC + 2.2 IntroductionPart I: A Introduction; B overall ACTD table of contents; C documents required for registration (application forms, labelling, Product Data Sheet, prescribing information)
2.3 QOS + Module 3Part II Quality: A ToC; B Quality Overall Summary; C Body of Data
2.4 / 2.6 + Module 4Part III Nonclinical: A ToC; B Overview; C Written and Tabulated Summaries (pharmacology, pharmacokinetics, toxicology); D Study Reports
2.5 / 2.7 + Module 5Part IV Clinical: A ToC; B Overview; C Clinical Summary (biopharmaceutics, clinical pharmacology, efficacy, safety, synopses); D Tabular listing of all clinical studies; E Clinical study reports; F Key literature references

Source for the ACTD column: ACTD Rev.1, pp.4-6.

Main differences

1. You can change the layout.

  • ICH M4 says applicants "should not modify the overall organisation" of the CTD [2].
  • The ACTD calls itself "merely" a write-up format. It says applicants "can modify, if needed, to provide the best possible presentation" of the technical data (ACTD Rev.1, p.4).

2. Nonclinical and clinical Parts depend on the type of application.

  • Parts III and IV are "not required for Generic Products, Minor Variation Products and some Major Variation Products."
  • For new chemical entities (NCEs), biologicals and other major variations, the study reports "may not be required" if the original product is already approved in Reference Countries. The authority that needs specific reports "should ask" for them.
  • So an ASEAN generic dossier is essentially Part I plus Part II (ACTD Rev.1, p.5).

3. Quality requirements differ by product category.

  • Part II is a table showing which items apply to NCE, Biologics and Generics (G).
  • Examples for generics:
    • Some items take "compendial requirements or appropriate information from the manufacturer".
    • Pharmaceutical development components can be supported by "literature data".
    • Drug substance stability can be literature data plus a stability summary (ACTD Part II Quality, pp.8-12).
  • The section codes (S1-S7, P1-P5 and so on) follow the familiar 3.2.S / 3.2.P logic. The biologics rows add cell bank, viral safety and inactivation items (pp.9-10).

4. Content comes from ASEAN and national rules.

  • The Body of Data "merely indicates where the information should be located." The type and extent of data "may depend upon national guidance" and pharmacopoeias.
  • For NCEs and biologics, it refers you to the relevant ICH guidelines.
  • It tells applicants to consult the relevant National Regulatory Authorities on whether the format applies to their product.
  • The quality content requirements sit in the ASEAN Common Technical Requirements (ACTR) (ACTD Part II Quality, p.8).

5. Variations and biosimilars use other guidance.

  • The ACTR Quality covers new registrations only.
  • For variations, the ACTD points to:
    • pharmaceuticals: the ASEAN Variation Guideline;
    • biotherapeutics: the WHO 2017 guidelines on changes to approved biotherapeutic products;
    • vaccines: WHO TRS 993, Annex 4 (ACTD Part II Quality, p.8).
  • The ACTD format also applies to biosimilars, even though the ACTR has no specific biosimilar requirements (ACTD Rev.1, p.4).

6. Formatting is mostly the same, with small differences.

  • Same as ICH: A4 or 8.5 x 11" margins and Times New Roman 12-point.
  • Each Part starts at page 1, and acronyms are defined the first time they appear in each Part.
  • References follow the 1979 Vancouver Declaration, where ICH M4 cites ICMJE style [27].
  • The ACTD presents itself as a paper-format guideline that "will ease" electronic submission "in the future" (ACTD Rev.1, p.4). It does not set an eCTD specification the way the EU and FDA rules do.

Converting an ICH CTD:

  • Move the 2.2 Introduction into Part I.
  • Put the QOS, Nonclinical Overview and Clinical Overview at the front of their own Parts.
  • Replace Module 1 with each country's Part I documents (application form, labelling, Product Data Sheet).
  • Then confirm with each national authority whether it wants Parts III and IV, or any study reports.

If you name the target ASEAN countries and the product type (NCE, biologic, generic or variation), I can look up their national requirements.

Q.03